Probably not a good way to phrase it. But from the statements these three patients had recurrent aortic stenosis with ischaemic heart disease and the company's valve was deemed the best option to improve haemodynamic function while allowing or preserving coronary artery catherter access. That's a pretty good endorsement considering the number of existing competitors with approval.
Probably not a good way to phrase it. But from the statements...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.00 |
Change
0.250(1.33%) |
Mkt cap ! $365.2M | |||
| Open | High | Low | Value | Volume |
| $18.51 | $19.09 | $18.25 | $574.5K | 30.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 84 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.10 | 55 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.09 |
Change
0.250 ( 3.08 %) |
||||
| Open | High | Low | Volume | ||
| $18.49 | $19.09 | $18.48 | 463 | ||
| Last updated 15.56pm 31/05/2024 ? | |||||
| AVR (ASX) Chart |